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Abstract
Microbiologists have extensively worked during the past decade on a particular phase of the bacterial cell cycle
known as biofilm, in which single-celled individuals gather together to form a sedentary but dynamic community
within a complex structure, displaying spatial and functional heterogeneity. In response to the perception of
environmental signals by sensing systems, appropriate responses are triggered, leading to biofilm formation. This
process involves various molecular systems that enable bacteria to identify appropriate surfaces on which to
anchor themselves, to stick to those surfaces and to each other, to construct multicellular communities several
hundreds of micrometers thick, and to detach from the community. The biofilm microbial community is a unique,
highly competitive, and crowded environment facilitating microevolutionary processes and horizontal gene transfer
between distantly related microorganisms. It is governed by social rules, based on the production and use of
“public” goods, with actors and recipients. Biofilms constitute a unique shield against external aggressions,
including drug treatment and immune reactions. Biofilm-associated infections in humans have therefore generated
major problems for the diagnosis and treatment of diseases. Improvements in our understanding of biofilms have
led to innovative research designed to interfere with this process.
Review
Inside biofilms
Biofilm notion is based on single-celled unicellular indivi-
duals (bacteria, fungi, or yeasts) forming a sedentary
community within a complex structure, displaying spatial
and functional heterogeneity [1]. Bacterial biofilms
account for a particular problem for human health,
because they are responsible for several infectious dis-
eases, associated with many inert surfaces, including
medical devices for internal or external use. They are
additionally suspected to be present in hospital water
networks and as reservoirs may lead to subsequent
acquired infections after patients’ hospitalization.
The presence of biofilms is probably underestimated,
principally because of the need for in vivo diagnosis [2].
Early studies described biofilms as an aspect of microbial
physiology [3], which almost all bacterial species can adopt.
The multicellular structure of the biofilm makes it possible
for the bacteria concerned to undergo dormancy and
hibernation, enabling them to survive and to disseminate
their genomes. It may therefore be considered as a step in
the bacterial cell cycle.
Biofilms also display unique properties, such as multi-
drug tolerance and resistance to both opsonization and
phagocytosis, enabling them to survive in hostile environ-
mental conditions and to resist selective pressures [4]. It
seems that host immunity is totally ineffective at clearing
these microcommunities and evidence has been obtained
that shows that immune cells are paralyzed with impeded
phagocytosis capacities [5] or decreased burst response
after phagocytosis with lowered production of reactive
oxygen species [6]. This community also is unique in that
it brings together different species in a structure in which
they can cooperate, rather than compete. The biofilm
thus constitutes a microbial society, with its own set of
social rules and patterns of behavior, including altruism
and cooperation, both of which favor the success of the
group [7,8] with task-sharing behavior, on the one hand,
and competition [9], on the other. Certain subpopula-
tions may display specialization. All of these patterns of
behavior are orchestrated by communication, which may
be chemical or genetic [10]. The biofilm thus constitutes
a unique way to stabilize interactions between species,
inducing marked changes in the symbiotic relationships
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community [11].
This multicellular arrangement also creates chemical
and metabolite gradients and heterogeneity in oxygen
availability. As such, it is a potentially stressful environ-
ment for aerobic species, necessitating adaptation to
oxygen paucity [12]. Starvation is an important trigger of
stress responses [13] and is associated with changes in
metabolic and catabolic pathways and with signs of mem-
brane stress [14,15]. Stressful associated conditions in bio-
films represent a unique way to generate genetic diversity
additionally and to drive evolution. The emergence of new
subpopulations, such as small-colony variants (genetic or
adaptative diversification), persisters, and cells tolerant to
imposed constraints, represents a new challenge for
microbiologists, who will need to develop an integral, hol-
istic view of the community. Common biofilm properties
have been defined, such as the need for a substrate and
“preconditioning surfaces,” the specialization of subpopu-
lations (known as “division of labor” [16]), the production
of a hydrated matrix shaping the community, and the divi-
sion of this life cycle into stages (Figure 1).
Biofilms, like other communities, form gradually over
time. Whatever the bacterial species involved and the
complexity of the resulting community, biofilm formation
is a dynamic process highly dependent on environmental
signals, passing through a four-stage universal growth
cycle consisting of initiation, maturation, maintenance,
and dissolution phases, regardless of the phenotype of the
constituent microorganisms [17]. Despite some common
traits, generalizations cannot be made in particular when
considering that it mostly associates multiple species.
Why are biofilms difficult to treat?
Biofilms in vivo are very difficult to diagnose essentially
due to the lack of sampling methods and markers, but
bacterial cell clusters in discrete areas in the host tissue
associated with host inflammatory cells can signal such
biofilm infections [18]. Chemical, physiological, and
genetic heterogeneity of the embedded bacterial popula-
tion increases over both space and time [19] (Figure 1).
This has been observed in Staphylococcus aureus bio-
films, in which cells exist in at least four distinct states:
aerobic growth, fermentative growth, dead, and dormant
[20].
Multidrug resistance, more than any other property of
biofilms, provides a clear demonstration that population
behavior is not the sum of the contributions of single
cells. Biofilms are unique multicellular constructions of
bacteria from one or several species, in which horizontal
genetic transfer may occur easily, thus facilitating cross-
breeding of resistance genes. The bacteria within biofilms
are embedded in a matrix of exopolysaccharides (EPS)
that they produce themselves. This matrix limits
antibiotic diffusion. The association of molecules of var-
ious types within the biofilm, including EPS and DNA,
constitutes a physical barrier to the diffusion of antimi-
crobial agents. However, many studies have surprisingly
shown that the penetration of antibiotics is not limited in
bacterial biofilms. For example, fluoroquinolones diffuse
rapidly within Pseudomonas aeruginosa [21] and Kleb-
siella pneumoniae [22] biofilms, tetracycline diffuses
rapidly in Escherichia coli biofilms [23], and vancomycin
diffuses rapidly in Staphylococcus epidermidis biofilms
[24]. Aminoglycosides are the only molecules for which
poor penetration has been reported in biofilms of an algi-
nate (the mucoid EPS)-producing strain of P. aeruginosa
[25]. As EPS differ considerably between, and even within
species, the limited diffusion of antimicrobial drugs
within bacterial biofilms certainly has been underesti-
mated. Regulation of specific drug resistance-associated
genes due to unique environmental stresses or starvation
conditions can be observed in bacterial biofilms. These
conditions may favor the emergence of dormant cells
called persisters [26].
Persisters are in a particular physiological state with
low levels of translation but a unique gene expression
profile [27], associating the switch off of genes encoding
metabolic proteins together with operons encoding
toxin-antitoxin pairs switched on. The latter probably
play a role in competition in addition to contribute to
dormancy. However, persister cells, which are resistant to
killing by antibiotics and can survive drug treatment,
account for only a small proportion of the biofilm popu-
lation [28]. Indeed, when dispersed mechanically, most
biofilm cells seem to be as susceptible to inhibitors as
planktonic cells. A number of cells are drug-tolerant
because of their particular physiological state in the bio-
film, due to nutrient and oxygen limitation, for example.
Some resistance mechanisms may be stronger in biofilms,
given that specific efflux pumps have been shown to be
more efficient in P. aeruginosa [29] and E. coli [30] bio-
films. However, this mechanism is not universal, and
some efflux pump inhibitors can reduce or even abolish
E. coli biofilm formation [31].
A novel mechanism of biofilm-associated antibiotic
resistance has been described recently in P. aeruginosa:
released DNA, the highly anionic polymer working as a
cation chelator in the extracellular matrix, creates a loca-
lized cation-limited environment. This cation-starvation
is detected by P. aeruginosa, leading to the induction of
LPS modification genes and resistance to antimicrobial
drugs, such as cationic antimicrobial peptides and amino-
glycosides [32]. Another interesting biofilm-specific resis-
tance mechanism also has been identified in this
bacterium. The biofilm ndvB-dependent production of
glucans in the periplasm leads to aminoglycoside seques-
tration in this cellular compartment, preventing them
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unique to P. aeruginosa biofilms [33]. In multimicrobial
biofilms containing Candida albicans and S. aureus, such
as that occurring on the surface of indwelling medical
devices, resistance of S. aureus to vancomycin is higher
in the polymicrobial biofilm. This increased resistance of
S. aureus requires viable C. albicans and is mediated in
part by the C. albicans matrix [34], although C. albicans
growth and sensitivity to amphotericin B are not altered
in the polymicrobial biofilm.
It is now widely accepted that life in a sedentary com-
munity confers a unique type of bacterial resistance,
known as biofilm-associated antimicrobial resistance. This
resistance is highly problematic for effective therapeutic
decisions, especially when considering that many resis-
tance phenotypes are shut down when bacterial samples
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Figure 1 Temporal evolution of biofilm. Schematization of the four-stage universal growth cycle of a biofilm with common characteristics,
including initiation (I), maturation (II and III), maintenance (IV), and dissolution (V). Steps in P. aeruginosa are presented labelled with DAPI (A-C),
chromosomal GFP (D) (personal data), or LIVE/DEAD BacLight kit (E) (Boles et al., 2005), observed with confocal microscopy and in S. aureus (F-H)
in scanning electron microscopy (personal data). Potential hacking strategies are presented, including limiting 1) switch from planktonic to
biofilm lifestyle (protein engineering of key players including c-di-GMP proteins, global regulators), 2) initial adhesion and interaction
(glycomimetics), 3) communication (compounds interfering with QS autoinducers), 4) reactivating metabolic activity for increasing antibiotic
efficiency (iron chelating procedure as an adjunct to conventional antibiotics), 5) developing anti-adhesive surfaces (silver or antiseptic-coated
surfaces for endotracheal tubes), and 6) promoting dispersion (NO, capsules or dispersin-like molecules, phages).
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teriological phenotypes.
How are biofilms built?
Our understanding of the molecular basis of bacterial
biofilm development has benefited from improvements
in genetics, genomics, and the development of visualiza-
tion techniques unraveling the processes involved in
biofilm development, physiology, and adaptation. A
plethora of systems that enable bacteria to identify and
anchor themselves onto appropriate surfaces, to stick to
each other, to construct multicellular communities sev-
eral hundreds of micrometers thick, and to detach from
the community has been identified and characterized in
many biofilm-forming bacteria (Figure 1). It is not possi-
ble to identify general molecular profiles for a given bac-
terial species, because some genes are important for
biofilm formation under both static and dynamic condi-
tions, whereas others are important only under dynamic
biofilm conditions [35]. However, throughout the bac-
terial kingdom, these genes can be separated into those
encoding appendages consisting of oligomerized subu-
nits responsible for motility (type IV pili or TFP, fla-
gella) or with other functions (fimbriae, other types of
pili, curli), EPS, surface adhesins, or other secreted ele-
ments. The molecular machines responsible for assem-
bling or secreting these systems are, of course, highly
dependent on the simple or double membranes of
Gram-positive and Gram-negative bacteria, respectively
[36,37]. Their role in biofilm initiation and structuring
also is highly dependent on environmental conditions
and the surfaces encountered by the bacteria [38]. Each
bacterial species has its own adhesion toolkit, containing
a number of molecules, different for each species that
may be used antagonistically or synergistically, depend-
ing on the situation with which the bacterium is faced.
Global expression at the patient bed is required to
understand how bacteria form biofilms in patients, espe-
cially when considering that in vivo bacterial situations
can widely differ with in vitro behavior [39].
What signals trigger biofilm structuration?
Biofilm formation is highly dependent on regulatory net-
works governing the switch between planktonic and
sedentary lifestyles. These networks integrate environ-
mental signals through adequate sensing systems trig-
gering appropriate responses, including two-component
and ECF signaling pathways, quorum sensing (a multi-
cellular response) resulting in the production of autoin-
ducers, which are small diffusible molecules [40,41] and
other molecules, including c-di-GMP [42] (Figure 2).
The stepwise formation of the biofilm, such as develop-
mental processes, involves the switching on of a specific
genetic program, leading to coordinated patterns of
gene expression and protein production.
Two-component system (TCS) and extracytoplasmic
function (ECF) signaling pathways are the major signal-
ing mechanisms used by bacteria to monitor external
and internal stimuli (e.g., nutrients, ions, temperature,
redox states) and translate these signals into adaptive
responses. The TCS pathways (Figure 2A) include two
proteins: a histidine kinase (HK) protein, called “sensor,”
and a cognate partner, called “response regulator” (RR).
Upon detection of the stimulus, the HK is activated and
auto-phosphorylates on a conserved histidine residue.
The phosphoryl group is then transferred onto a con-
served aspartate residue on the cognate RR [43]. Phos-
phorylation results in RR activation, which is most
frequently a transcriptional regulator. As an example,
the GacS (HK)/GacA (RR) TCS is one of the major sys-
tems involved in the control of P. aeruginosa biofilm
formation. Once activated by an unknown signal, the
GacS/GacA TCS switches on the transcription of the
rsm genes. The rsm genes encode two small non-coding
RNA (sRNA), RsmY and RsmZ, of which the expression
level is a key player in controlling switch between plank-
tonic and biofilm lifestyles [44]. High expression of rsmY
and rsmZ leads to high biofilm formation, whereas a
reduced expression of them is associated with an
impaired biofilm formation. The Gac regulatory pathway
has been linked to two additional HK RetS and LadS.
Although RetS has been demonstrated to antagonize
GacS, thus repressing genes required for biofilm forma-
tion [45], LadS reinforces GacS-dependent activation of
genes required for biofilm formation [46]. In parallel,
the Gac system activates antibiotic resistance toward
aminoglycosides (gentamicin and amikacin) and chlor-
amphenicol [47], thus linking once more biofilm lifestyle
and antimicrobial resistance. TCS-dependent regulation
of biofilm formation is widespread in many bacteria as
illustrated by the positive control exerted by the GraS
(HK)/GraR (RR) TCS on S. aureus biofilm induction
[48].
The second major signaling mechanism used by bac-
teria and probably underestimated is the ECF signaling
pathway (Figure 2B), which involves an alternative sigma
factor, an anti-sigma factor located preferentially in the
cytoplasmic membrane, sequestering and inhibiting its
cognate sigma factor [49] and one or several periplasmic
or outer membrane proteins required for the activation
of the pathway [50]. Upon perception of the extracellular
signal by the periplasmic or outer membrane proteins,
degradation of the anti-sigma factor induces releasing of
the sigma factor, which can promote the transcription of
a specific set of target genes. In P. aeruginosa, for exam-
ple, AlgU ECF sigma factor controls production of the
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[51]. The AlgU sigma factor functions with the anti-
sigma MucA, which C-terminal periplasmic domain is
cleaved by the AlgW protease in response to an unknown
signal [52].
Bacteria also use a multicellular response to coordinate
expression of genes required for biofilm in a population
density-dependent manner, called quorum sensing (QS)
(Figure 2C), defined as a bacterial communication pro-
cess utilizing small, diffusible molecules termed autoin-
ducers or pheromones. Autoinducers are different
between Gram-negative and Gram-positive bacteria,
using preferentially N-acyl-homoserine lactones and oli-
gopeptides, respectively. Autoinducers accumulate out-
side reflecting the growing population density and, upon
reaching a concentration threshold, regulate virulence
and pathogenicity genes. Detection of autoinducer
threshold may utilize a HK, or autoinducers can enter
passively or actively the cell and bind a regulator protein,
both combinations trigger a specific genetic response
[53]. In S. aureus, transition between planktonic and bio-
film lifestyles is predominantly controlled by QS. The
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Figure 2 Regulatory networks controlling transition between planktonic and biofilm lifestyle. The external frames illustrate the bacterial
envelope with one or two membranes (OM: outer membrane, IM: inner membrane) according to Gram-positive (C) and Gram-negative bacteria
(A, B, and D), respectively. A Control of biofilm formation in P. aeruginosa through the TCS GacS (HK)/GacA (RR) mediated by sRNA rsmY and
rsmZ gene transcription and modulated by RetS and LadS, two additional HK in P. aeruginosa. B Control of EPS alginate in P. aeruginosa, which
further impacts biofilm architecture by the system ECF sigma factor AlgU - anti-sigma MucA - AlgP (IM)-AlgW (periplasmic) complex: 1) activation
of AlgW/AlgP, 2) cleavage of MucA, 3) release of AlgU, 4) activation of the alg UmucABCD operon. C Control of S. aureus biofilm formation
through the Agr QS system: 1) AgrD autoinducer production, 2) AgrD autoinducer accumulation in the extracellular medium where it reaches a
threshold, 3) activation of the TCS AgrCA by AgrD at the threshold concentration, 4) AgrA-dependent activation of the sRNA RNA III expression
repressing expression of genes involved in biofilm formation together with amplification loop of agrABCD. D Control of P. aeruginosa biofilm
formation through the intracellular second messenger c-di-GMP level controlled by the FimX protein having DGC and PDE domains, a RR
domain, and a PAS domain. Note that in FimX protein only PDE activity is detectable (continuous arrow), whereas DGC activity is undetectable
(dotted arrow).
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encodes the autoinducer. Once produced, exported, and
present at the threshold concentration, AgrD pheromone
controls through the TCS AgrCA, the expression of the
small non-coding RNA, RNAIII; thus RNAIII down-regu-
lates genes encoding adhesins required for biofilm forma-
tion [54,55]. It thereby promotes dispersion together with
extracellular protease activity [56], linking inversely the
bacterial population size and biofilm formation together
with probable resistance to glycopeptides antibiotics [57].
Most glycopeptide-resistant S. aureus are agr dysfunc-
tioning even though the link between agr function and
glycopeptide resistance is still debated.
Finally, among signaling molecules is the intracellular
second messenger c-di-GMP (Figure 2D). The amount of
this messenger is tightly controlled, being increased by
the activity of diguanylate cyclases (DGC) carrying
GGDEF domains and decreased by the activity of phos-
phoesterases (PDE) carrying EAL domains. In bacteria,
high c-di-GMP levels are generally associated with the
stimulation of biofilm formation via the production of
adhesive surface organelles or EPS synthesis and a
decrease in motility.
Many proteins containing GGDEF or EAL domains are
linked to various N-terminal sensory input domains, sug-
gesting that several signals from the environment are
integrated through the c-di-GMP signaling pathway. In
P. aeruginosa, the FimX protein controls expression of
genes encoding Type IVa pili involved in early step of
biofilm formation [58]. FimX possesses both imperfect
DGC and PDE domains; however, only the PDE activity
is detectable. The FimX protein is associated with a RR
domain and a PAS domain; the latter is probably involved
in sensing oxygen and redox potential [59]. These signals
are potentially the activating signals.
The regulatory networks controlling transition between
planktonic and biofilm lifestyle are far from being eluci-
dated and involve intricate crosstalk between regulatory
pathways. These networks require extensive genetic stu-
dies to understand how bacteria integrate signals from the
environment to establish into multicellular communities.
Where can we hack?
Because this biofilm lifestyle may be associated with
human infectious diseases and account for 80% of bacter-
ial chronic inflammatory and infectious diseases, several
lines of research are currently focusing on the possibility
of hacking into biofilm initiation, structuration or com-
munication, and promoting dispersion [60] (Figure 1),
even though we are far from understanding the complex
genetic basis for biofilm formation in vivo.
Undoubtedly, due to antimicrobial tolerance, slow-
growing cells, and EPS matrix, biofilm-associated infec-
tions do not respond consistently to therapeutically
achievable concentrations of most antimicrobial agents.
Practicians, therefore, must integrate these notions to
direct clinical decision and further adapt antimicrobial
therapy to such types of combined infectious conditions.
This is particularly successful when antimicrobial lock
technique (ALT) is applied in particular to combat bac-
terial biofilms on central veinous catheters [61,62]. This
technique corresponds to an instillation of antimicrobial
drugs with bactericidal rather than bacteriostatic proper-
ties in the catheter in situ for a sufficient dwell time and
at high concentrations (mg/ml). However, for most stu-
dies that evaluate ALT in patients, true elimination of
bacterial biofilms has not been checked and treatment
success has been based on negative culture results of
blood samples or absence of clinical symptoms in
patients. Because very high doses of antimicrobials are
recommended, ALT can induce secondary antimicrobial
resistance and potential toxicity for the patient [62].
This technique has been tested with several other mole-
cules, such as chelating agents, ethanol, and taurolidine-
citrate and gives promising results for reduced incidence
of biofilms on central-venous access devices in human
studies [62].
Additionally, all new information concerning the func-
tioning of biofilms may potentially lead to strategies for
dismantling this microbial community [63] and actually
requires to be validated in vivo. Much effort has focused
on compounds interfering with QS autoinducers [64],
molecules enhancing dispersion, such as NO, capsules or
dispersin-like molecules and, recently, phages [65]. Alter-
ing general regulatory pathways by protein engineering of
key players also are very promising tracks (e.g., c-di-GMP
proteins, global regulators) [60,66]. For example, interfer-
ing with DGC protein activity and therefore with c-di-
GMPbiosynthesis would represent a promising track [67].
Sulfathiazole is a sulfonamide that has been identified as
the sole anti-biofilm molecule against E. coli strains and
acts indirectly on c-di-GMP levels by targeting nucleotide
synthesis rather than on DGC activity. Because anaerobic
growth within biofilms could depend substantially on iron
availability and is critical for biofilm-associated antimicro-
bial resistance, iron chelation has been proposed as an
adjunct to conventional antibiotics, such as aminoglyco-
side administration to disrupt variable-aged P. aeruginosa
biofilms [68,69]. Increasing efforts have been dedicated to
molecules interfering with adhesive structures and to the
development of new surfaces for internal or external medi-
cal devices [70]. This is illustrated by the recent demon-
stration of broad and high-level antimicrobial activity in
vitro of antiseptic-coated as well as silver-coated endotra-
cheal tubes to prevent adherence and biofilm formation of
drug-resistant bacteria (MRSA, MDR P. aeruginosa, MDR
Acinetobacter baumannii,E S B LK. pneumoniae, and MDR
Enterococcus cloacae) and yeasts (C. albicans) causing
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patients. The promising development of antiseptic-coated
devices requires additional animal studies and prospective,
randomized clinical trials to evaluate whether they poten-
tially induce emergence of bacterial resistance and reduce
the risk of VAP in critically ill patients [71].
Conclusions
There is a very dynamic research activity in the biofilm
field, especially because this bacterial lifestyle may be
associated with human infectious diseases. However, the
in vivo biofilms are far more complex than those studied
in vitro due to the underestimation of environmental
parameters or the numbers of species controlling bio-
film formation. Understanding the genetic basis of bio-
film formation in vitro together with the definition of
biofilm signatures in vivo in infected patients is a key
requirement for efficiently hacking into biofilm strategy.
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